JR-141 + JR-141 + JR-141
Phase 2Completed 0 watching 0 views this week⚡ Active
51
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Mucopolysaccharidosis II
Conditions
Mucopolysaccharidosis II
Trial Timeline
Jul 26, 2018 → Oct 4, 2019
NCT ID
NCT03359213About JR-141 + JR-141 + JR-141
JR-141 + JR-141 + JR-141 is a phase 2 stage product being developed by JCR Pharmaceuticals for Mucopolysaccharidosis II. The current trial status is completed. This product is registered under clinical trial identifier NCT03359213. Target conditions include Mucopolysaccharidosis II.
Hype Score Breakdown
Clinical
17
Activity
12
Company
9
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03359213 | Phase 2 | Completed |
Competing Products
20 competing products in Mucopolysaccharidosis II